FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FENNEC PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.27+0.29 (+2.91%)
Close on Oct 19, 2026
- Market cap
- $374.14M
- P/E (TTM)
- –
- Dividend yield
- –
Fennec Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $360.14M | $166.30M |
| Enterprise Value | $318.89M | $88.19M |
| PS Ratio | 6.08 | 3.65 |
| PB Ratio | 8.49 | 2.03 |
| P/TBV Ratio | 8.49 | 2.29 |
Enterprise value
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 5.38 | 2.51 |
Income (trailing twelve months)
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $59.22M | $58.34M |
| Operating Income | -$1.13M | -$21.40M |
| Net Income | -$3.25M | -$22.46M |
| EBITDA | -$1.13M | -$16.91M |
| EPS (Diluted) | -$0.11 | -$0.83 |
Margins
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -1.90% | -44.0% |
| Profit Margin | -5.49% | -40.2% |
| EBITDA Margin | -1.90% | -30.2% |
Returns
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -18.6% | -53.2% |
| Return on Assets (ROA) | -5.39% | -40.9% |
| Return on Capital Employed (ROCE) | -1.78% | -38.1% |
Growth
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 77.8% | 5.96% |
| Revenue Growth (3Y CAGR) | 207.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 194.9% | 6.48% |
Balance sheet
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $41.25M | $61.43M |
| Net Cash (Debt) | $41.25M | $15.35M |
| Net Cash Per Share | $1.18 | $0.66 |
| Equity (Book Value) | $42.44M | $49.09M |
| Book Value Per Share | $1.21 | $1.37 |
| Tangible Book Value | $42.44M | $23.52M |
| Working Capital | $60.11M | $76.81M |
Financial position
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 5.85 | 3.34 |
| Quick Ratio | 3.33 | 2.44 |
| Interest Coverage | -1.24 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.04M | -$12.35M |
Efficiency
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.98 | 0.39 |
| Revenue Per Employee | $1.69M | $404.87K |
| Profits Per Employee | -$92.89K | -$703.34K |
| Employee Count | 35 | 74 |
Dividends and yields
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -0.90% | -23.3% |
Shares
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 35,067,200 | 58,127,000 |
| Shares Change (YoY) | 21.6% | 10.9% |
| Shares Change (QoQ) | 1.43% | 0.54% |
| Shares Held by Institutions | 46.5% | 59.4% |
Scores
| Measure | Fennec Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 3.97 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Fennec Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.